REGULATION BRIEFING

Section 232 pharma tariffs explained: what they are and their impact on pharma manufacturing

The US Section 232 pharma tariffs put a 100% default duty on imported patented medicines, their APIs and key starting materials. They have applied to every importer since 29 September 2026, but trade deals, pricing agreements and onshoring plans cut the rate for most of the market. The heaviest exposure falls on mid-sized sponsors without deals, their non-US suppliers and the US CDMOs they could move work to.

Section 232 pharma tariffs: latest updates

Section 232 pharma tariffs at a glance

Full nameProclamation 11020, Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (91 FR 18183)
RegionUnited States
ThemeProtectionist
Legal statusIn force
ImplementationApplying: since 31 July 2026 for 17 large manufacturers, since 29 September 2026 for all others
Products coveredPatented drugs listed in the FDA Orange Book or Purple Book, their APIs and key starting materials. Generics, biosimilars and US-origin products are excluded for now
Tariff rates100% default; 15% for the EU, Japan, South Korea, Switzerland and Liechtenstein; 0% additional for the UK; 20% with an onshoring plan, rising to 100% on 2 April 2030; 0% with an onshoring plan and MFN pricing deal until 20 January 2029
Who is impactedMid-sized and smaller branded sponsors without deals, non-US API and key starting material suppliers, US CDMOs
Policy uncertaintyMedium: treatment of generics, approval of onshoring plans and future rate changes are still open
PharmaSource Score810 (rank 1)
Impact 9, Reach 9, Likelihood 10
Download the PharmaSource Regulatory Radar

What the Section 232 pharma tariffs are

The Section 232 pharma tariffs are US import duties on patented medicines and their ingredients, imposed on 2 April 2026 under the national-security clause of the Trade Expansion Act of 1962. Proclamation 11020 cites FDA figures that about 53% of patented drugs distributed in the US are made abroad. Because they rest on Section 232, the tariffs fall outside the February 2026 Supreme Court ruling that struck down the emergency-powers tariffs.

The Section 232 pharma tariffs set a 100% default rate, which includes the ordinary customs duty, then cut it for most imports. Where several rates could apply, the lowest one counts:

  • Trade-deal partners. Products of the EU, Japan, South Korea, Switzerland and Liechtenstein pay 15% in total. UK products pay no additional duty.
  • Onshoring plans. Companies with a Commerce-approved onshoring agreement pay 20%, rising to 100% on 2 April 2030.
  • Onshoring plus MFN pricing. Companies that pair an onshoring plan with a most-favored-nation pricing deal pay nothing until 20 January 2029.
  • Specialty products. Orphan-only drugs and other specialty categories enter at zero if they come from an eligible trading partner, a list that excludes China, or win an urgent US health need approval, filed one product at a time.

Generics, biosimilars and US-origin products sit outside the tariffs for now. Commerce has also exempted products imported only for clinical trials or R&D, and confirmed that excipients are not covered.

How the trade-deal caps work: EU, Switzerland, Japan and the UK

The 100% rate is only the default. Most branded drugs imported into the US come from countries whose trade deals cap the total duty. Brookings senior fellow Marta Wosińska told CDMO Live Americas that “the vast majority of them are going to be exposed to 15% tariffs.” South Korea also pays 15%. The four deals below set what most European and Japanese product actually pays.

  • European Union (15%, all-inclusive): The August 2025 EU-US joint statement caps the combined US tariff on EU pharmaceuticals at 15%. That figure includes the standard MFN duty and any Section 232 tariff. “All-inclusive” means the 15% is a ceiling, with no stacking on top. Generic medicines, their ingredients and chemical precursors pay only the standard MFN rate.
  • Switzerland and Liechtenstein (15%, with an investment pledge): The November 2025 deal cut the Swiss rate from 39% to 15% and caps pharmaceuticals at 15%. In return, Swiss companies pledged at least $200 billion of US investment by the end of 2028, with at least $67 billion in 2026. The total includes earlier commitments, such as Roche’s $50 billion.
  • Japan (15%, with an investment pledge): Japanese goods pay a baseline 15%, and Japan’s negotiators say the deal guarantees Japan the lowest pharmaceutical rate of any US trade pact. Japan committed up to $550 billion in loans, guarantees and investment for US projects. Generics are carved out of the 15% tariff.
  • United Kingdom (0%, in exchange for pricing): UK pharmaceutical exports, patented and non-patented, enter at 0% for at least three years. In return, the UK raised NICE’s cost-effectiveness threshold from £20,000–£30,000 to £25,000–£35,000 per QALY, and capped VPAG payback at 15% for 2026 to 2028.

For outsourced manufacturing, the country where a product is made now sets its tariff. Product from an EU, Swiss or Japanese CDMO pays 15%, and product from a UK site pays nothing. Product from a country without a deal, such as India, Israel or Singapore, faces the full 100% unless the sponsor has an onshoring or MFN pricing agreement.

Where the Section 232 pharma tariffs stand

The Section 232 pharma tariffs are fully in force. The open questions are which companies win reduced rates, and whether the tariffs reach generics, which Commerce must advise on by 2 April 2027.

  • 1 April 2025: Commerce opens the Section 232 investigation.
  • 2 April 2026: The President signs Proclamation 11020.
  • 13 May 2026: Commerce opens applications for onshoring agreements, due by 12 June.
  • 31 July 2026: Tariffs apply to the 17 Annex III manufacturers.
  • 29 September 2026: Tariffs apply to all other companies.
  • By 2 April 2027: Commerce advises the President on whether to extend the tariffs to generics.
  • 20 January 2029: The zero rate for companies with onshoring plans and MFN deals ends.
  • 2 April 2030: The onshoring rate rises from 20% to 100%.

What the Section 232 pharma tariffs mean for manufacturing and outsourcing

The Section 232 pharma tariffs turn the location of each manufacturing step into a cost line for every branded product sold in the US. The headline rate overstates the exposure. At CDMO Live Americas 2026, Brookings senior fellow Marta Wosińska told PBOA president Gil Roth that most branded imports come from trade-deal countries capped at 15%. “Onshoring only brings it down to 20%, and they’re already at 15%,” she said.

  • Large pharma. The 17 companies that signed deals represent roughly 86% of branded sales, Wosińska told the conference’s opening panel. They pay nothing until 2029, and many are building their own US plants, with pledges such as Merck’s and Pfizer’s running to $70bn each.
  • Mid-sized and smaller sponsors. The most exposed group. About 300 sponsors hold NDAs or BLAs, and nearly 200 remain exposed once orphan drug holders are removed. “A lot of them just have one product,” Wosińska said. “They’re your clients.” Flamma vice president Kenneth Drew said these companies “weren’t able to go to Washington and cut deals,” and some say they have been left without guidance on exemptions.
  • CDMOs. At PBOA’s urging, a contract with a domestic CDMO counts as onshoring, and the reduced rate under an onshoring agreement can be used by companies other than the manufacturer. Roth calls CDMO capacity a force multiplier because it serves many sponsors.
  • Non-US suppliers. Using USP’s Medicine Supply Map, Wosińska identified India as the largest group facing the full 100%, with Israel and Singapore also exposed. China matters less because its role centers on early development, and clinical supplies are exempt.
  • Sponsors supplied from Europe, Japan or Korea. A tech transfer to the US buys little without an MFN deal. For a small biotech working with a European CDMO, Wosińska said, “You might be willing to absorb 15%.”

Not everyone expects a large shift. Oliyai Consulting CEO Reza Oliyai argued that for high-cost branded medicines, tariffs and cost of goods are a small share of what patients pay, and that sponsors can redesign supply chains around many tariffs. For outsourcing leaders, the practical work is product by product: where each product enters the US, which origin customs assigns it, and which agreements the company holds.

Why supporters back the Section 232 pharma tariffs

“America must manufacture pharmaceutical products in order to be safe, secure, and healthy.”

The White House, fact sheet on Proclamation 11020

The administration and domestic producers back the Section 232 pharma tariffs for three reasons:

  • Security of supply. The proclamation argues that reliance on imported patented drugs could cut off access in a geopolitical or economic shock, and that a domestic base supports defense and public health.
  • Investment. The White House says the threat of tariffs has already drawn about $400bn in investment commitments to the US.
  • Leverage on prices and new demand for US capacity. Tying lower rates to MFN deals brought every named large manufacturer to an agreement by 31 August. Smaller sponsors are now, in Wosińska’s words, “banging at the doors of CDMOs” to escape the tariffs, and US producers such as Arizona API maker Bright Path welcomed the proclamation.

Criticisms of the Section 232 pharma tariffs

“Tariffs are not a good tool for getting at the national security risk.”

Marta Wosińska, Senior Fellow, Brookings Institution, speaking at CDMO Live Americas 2026

The main criticism is that the Section 232 pharma tariffs miss their target and fall hardest on the companies least able to respond. National security concerns center on key starting materials, Wosińska noted, yet the rate follows where the API is made. Large manufacturers have deals, while smaller biotechs face the full rate. “A 20% tariff could be absorbed by a branded manufacturer,” she said. “But 100% tariff puts your back against the wall.” Biocom warned that small and mid-sized innovators would be hit disproportionately.

Other concerns:

  • Higher costs and slower innovation. PhRMA and BIO both warned that tariffs would raise costs and undermine domestic manufacturing and drug development.
  • Pledges that may not be built. Pharma has pledged more than $500bn for US manufacturing, but 68% of the CDMO Live Americas audience said less than a quarter has reached concrete projects. “There’s more bark than bite,” Oliyai said.
  • Timelines. Moving supply means tech transfer, validation and regulatory filings. At ExM Leaders Basel, one outsourcing leader said “it takes four years to set up a new API supplier,” longer than the policy may last.
  • Contract capacity. Roth set in-house pledges in the tens of billions against CDMO commitments of hundreds of millions. On sterile fill-finish, sponsors at ExM Leaders Boston said they are booking 18 months ahead.
  • Short-lived gains for CDMOs. Oliyai told CDMOs that “the tariffs are not going to save the U.S. and EU CDMO industry,” and Wosińska questioned whether sponsors fleeing the tariffs will stay once policy shifts.
  • Generics next. The President has announced generics tariffs of 100% in 2028 and 200% in 2029. With thin margins, Wosińska warned, “you either will have shortages, or you’re going to push manufacturers closer towards China.”

What’s next for the Section 232 pharma tariffs

The rates are set. As Roth put it, the gap between what gets announced and what gets implemented is the space to watch. Five things decide who pays:

  • The generics decision. Commerce advises the President by 2 April 2027, and Wosińska expects news on generics and biosimilars in April.
  • Onshoring approvals. Which applicants Commerce approves, and on what terms, sets how far the 20% rate reaches.
  • Deals for smaller companies. Whether mid-sized biotechs gain a practical route to MFN or onshoring relief.
  • The 2029 and 2030 deadlines. The MFN zero rate ends on 20 January 2029 and the onshoring rate rises to 100% on 2 April 2030, so US capacity started now has to be running by then.
  • Our score. The PharmaSource Regulatory Radar ranks the Section 232 pharma tariffs first of 39 policies, with a score of 810.

Related articles

Tracking global policies and their impact on biopharma manufacturing
REGULATORY RADAR
Full tracker of regulation changing biopharma manufacturing and supply.
Free to access and updated daily.